2020 Guide to Patient Support Services


Eisai Reimbursement Resources is a program designed to offer drug-specific assistance related to the coding, coverage, and reimbursement of select Eisai drugs, as well as a variety of patient assistance services for patients who are prescribed Eisai’s drugs and who are having difficulty paying for the cost of their care.

Eisai oncology drugs that are covered through Eisai Reimbursement Resources are listed in the Table.

The resources provided by Eisai Reimbursement Resources are drug-­specific; therefore, patients and providers are encouraged to visit EisaiReimbursement.com and select their prescribed medication for more information on programs specific to that drug.

These resources are available for patients in a variety of care settings and with different types of insurance coverage, including government and commercial insurance.

For more information visit EisaiReimbursement.com.


$0 Co-Pay Program

For commercially insured patients who have been prescribed an Eisai medication, drug-specific savings programs may be available.

The $0 Co-Pay Program provides assistance for patients with commercial insurance who have been prescribed Halaven (eribulin mesylate) or Lenvima (lenvatinib).

Eisai Assistance Program

Through the drug-specific assistance programs, certain medications may be available at low cost or no cost to financially needy patients who meet the program’s eligibility criteria, including US residency, income status, and site-of-service specifications.

Coverage and payment depend on the patient’s insurance plan. Drug-specific reimbursement information, insurance verification processing, prior authorization information, and guidance regarding denied claims may also be available with the Eisai Assistance Program.

For drug-specific information, please call 866-613-4724 or visit EisaiReimbursement.com.

Halaven $0 Co-Pay Program

Most patients who have been prescribed Halaven for an approved indication, through this program will pay $0 of their medication cost-sharing (coinsurance), and Eisai will pay up to a maximum of $18,000 annually of the medication cost that is not covered by insurance.

Lenvima $0 Co-Pay Program

Through this program, most patients who have been prescribed Lenvima for an approved indication will pay $0 of their medication cost-­sharing (coinsurance), and Eisai will pay up to a maximum of $40,000 annually of the medication cost that is not covered by insurance.

Depending on the insurance plan, additional financial responsibilities may be required. The savings program cannot be used in combination with other coupons or offers, and is not available to patients with state or federal healthcare programs. For more information, visit the specific website listed in the Table.

Eisai Patient Assistance Program

Patients who need assistance paying for their Eisai oncology medication should apply to the Eisai Patient Assistance Program, available at EisaiReimbursement.com. Patients with financial needs who meet the program eligibility criteria may receive Halaven or Lenvima at no cost through the Partnership for Prescription Assistance program.


The completed enrollment forms for the Eisai Patient Assistance Program, Halaven $0 Co-Pay Program, or Lenvima $0 Co-Pay Program should be faxed or mailed, together with a valid prescription, to the respective fax number or address listed on the drug-specific form, which can be accessed via EisaiReimbursement.com.

Application to the Eisai Patient Assistance Program should be mailed to the address on the application form. Healthcare providers can call the drug-specific Patient Assistance Program at 866-613-4724, to determine patient eligibility.

A copy of the patient’s insurance card, and any financial documents, should be attached. Accepted financial documents include a federal tax return, a Social Security benefit statement, and 1 month of paycheck stubs, unemployment statements, or disability statements.


Patient support programs

Halaven (eribulin mesylate)
Treatment of metastatic breast cancer; unresectable or metastatic liposarcoma
Patient support programs

Lenvima (lenvatinib)
Treatment of progressing differentiated thyroid cancer; advanced renal-cell cancer, in combination with everolimus; first-line treatment for unresectable hepatocellular carcinoma; treatment, in combination with pembrolizumab, of patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient, whose disease progressed after previous systemic therapy and who are not candidates for curative surgery or radiation
Patient support programs

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: